The Expression Of Stathmin In Ovarian Cancer And The Effect On Chemosensitivity To Cisplatin In Ovarian Cancer Cells

【Objective】To investigate the expression of Stathmin/Op18 in epithelial ovarian cancer and analyze the relationship between Stathmin/Op18 and clinical patholoical parameters.【Methods】22 cases of normal ovarian tissues, 16 cases of benign ovarian tumors and 50 cases of epithelial ovarian cancers were examined by polymerase chain rection(PCR) and immunohistocical staining.【Results】The Stathmin mRNA expression in ovarian epithelial cancer was higher than in normal and benign tumor tissues(P<0.05). The immunohistochemical analysis demonstrated that the positive rate of Stathmin in epithelial ovarian cancers group was higher than that in benign ovarian tumor and ovarian cancer group (74.00% vs 31.25%, 9.09%, P < 0.01). The difference between normal ovarian tissue and benign ovarian tumor group had no significance (P>0.05). The expression of Stathmin was related to clinical stages, histological grade and lymph node metastasis(P<0.05), but not age and the amount of ascites.【Conclusion】Stathmin overexpression may correlate with the occurrence and progression of epithelial ovarian cancer. 【Objective】The aim of the study was to reveal the different expression of the Stathmin/Op18 in ovarian cancer cells and explore the roles of Stathmin/Op18 gene in proliferation, apoptosis and chemosensitivity to cisplatin in human ovarian cancer cells.【Methods】The expression of Stathmin/Op18 in OV2008 and C13K cells was detected with Realtime PCR and Western Blot, We in vitro synthesized siRNA and transfected cell line with high expression of Stathmin, and detected jamming efficiency by Realtime PCR and Western Blot. The proliferating curve changes before and after transfected were measured by MTT assay. Cell apoptosis and cycle changes were determinated by flow cytometric analysis. Cells chemosensitivity to cisplatin was detected by MTT method.【Results】Expression of Stathmin/Op18 in C13K cells was significantly higher than that in OV2008 cells, Transfection of Stathmin/Op18 siRNA into C13K cells remarkably down-regulated expression of Stathmin/Op18. Down-regulated expression of Stathmin/Op18 by transfection could suppress cell proliferation and increase cisplatin chemosensitivity.【Conclusion】To interfere with Stathmin can effectively restrain ovarian cancer cell proliferation and effectively reverse ovarian cancer of platinum-based drug-resistant. siRNA technology may become a new method to overcome cancer and provide new prospects for the treatment of ovarian cancer.